Spartalizumab (anti-PD-1)

Catalog No.A2017 Synonyms: PDR001 Humanized and Non-humanized mouse model applicable

For research use only. Not for use in humans.

Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1.

Size Price Stock Quantity  
USD 707 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Quality Control

Choose Selective PD-1/PD-L1 Inhibitors

Biological Activity

Description Spartalizumab (anti-PD-1) is a humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1. It binds to PD-1 with high affinity and inhibits the biological activity of PD-1.
Targets
PD-1 [1]
()
In vivo In phase 1/2 studies, PDR001 has a manageable safety profile and preliminary antitumor activity in advanced solid tumors[1].

Protocol

Product Details

Formulation PBS buffer, pH 7.2
Isotype Human IgG4
Source CHO cells
Storage Store the undiluted solution at 4 °C in the dark and avoid freezing

Tech Support

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to store the antibody?

  • Answer:

    Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.

Tags: buy Spartalizumab (anti-PD-1) | Spartalizumab (anti-PD-1) supplier | purchase Spartalizumab (anti-PD-1) | Spartalizumab (anti-PD-1) cost | Spartalizumab (anti-PD-1) manufacturer | order Spartalizumab (anti-PD-1) | Spartalizumab (anti-PD-1) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID